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Background: Suboptimal treatment response during anti-depressive treatment is fairly
common with the first antidepressant (AD) choice, followed by switching to another agent
in the majority of cases. However, the efficacy of this strategy over continuation of the
original agent is less solidly documented in real-life studies. The aim of our present study
was to ascertain the effects of switching to duloxetine following inadequate response to
prior ADs on general illness severity, pain, and health-related quality of life in a large
sample of major depressive disorder (MDD) and generalized anxiety disorder (GAD)
patients in a prospective, real-world, multicenter, observational study.
Methods: A total of 578 participants with MDD or GAD were enrolled in 58
outpatient sites in an 8-week, single-arm, open-label, flexible-dose trial with duloxetine.
Severity of symptoms [with Clinical Global Impression-Severity (CGI-S) and Clinical
Global Impression-Improvement (CGI-I)], severity of pain (with a Visual Analog Scale),
satisfaction with current treatment, and health-related quality of life [with the three-level
version of the EuroQol five-dimensional questionnaire (EQ-5D-3L)] measures were
recorded at baseline and at follow-up visits 4 and 8 weeks after initiation of treatment.
Data were analyzed using ANOVA and mixed linear models.
Results: 565 patients completed the study and comprised the analyzed dataset.
Results indicated that severity of illness significantly decreased over the 8 weeks
of the study and already at 4 weeks in both patient groups. Overall quality of
life and all of its subindicators also significantly improved in both patient groups
and so did subjective experience of pain. Satisfaction with current treatment also
significantly increased during the study period. Frequency of side effects was
low. In both GAD and MDD groups, two patients dropped out of the study
due to adverse effects, leading to treatment termination in four cases (0.7%).
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Conclusions: This 8-week, multicenter, flexible-dosing, single-arm, open-label,
observational real-life study in MDD and GAD patients switched to duloxetine after
inadequate response or low tolerability to other ADs showed a significant positive effect
on all outcome measures, including a significant decrease in illness severity as well as
significant overall symptomatic improvement, with good tolerability.
Keywords: major depressive disorder, generalized anxiety disorder, duloxetine, health-related quality of life,
clinical global impression scale

INTRODUCTION

The objective of the current study was to ascertain the effects
of the commencement of duloxetine treatment on general illness
severity, symptomatic improvement, pain, and health-related
quality of life in a real-world observational study among patients
with MDD or GAD without adequate response to and/or with
remarkable side effects during treatment with a prior AD.

Duloxetine is a frequently used psychotropic agent that belongs
to the serotonin–norepinephrine reuptake inhibitor (SNRI) type
of antidepressants (ADs) (1, 2) and is used to treat both
psychiatric [major depressive disorder (MDD) and generalized
anxiety disorder (GAD)] and non-psychiatric (e.g., diabetic
neuropathic pain, fibromyalgia, stress incontinence) conditions
(3, 4). Members of the SNRI family differ from each other
in their affinity/selectivity to serotonin and norepinephrine
transporters (SERT and NAT, respectively). In this regard,
duloxetine has relatively balanced inhibitory properties on these
two monoamine transporters. It means that duloxetine has
10-fold greater selectivity for serotonin over norepinephrine
reuptake inhibition (the corresponding ratios are about 30 for
venlafaxine, 14 for desvenlafaxine, and 1.6 for milnacipran)
(1, 5). Duloxetine also has a weak inhibitory effect on
dopamine transporters (3), which is also observed in case of
venlafaxine when its dose is higher than 300 mg/day (5). This
multitarget action mechanism underlies the robust efficacy of
duloxetine in the treatment of a wide range of symptoms
associated with mood and anxiety disorders and also its painrelieving effect, which is the most pronounced in the SNRI
group and is independent of the presence of depression or
anxiety (1, 2, 5, 6).
It is well-known from both clinical studies and everyday
practice that suboptimal response (or even non-response)
to AD treatment is not uncommon. The STAR∗ D and the
European Group for the Study of Resistant Depression
trials showed that about 35% of subjects fail to achieve
therapeutic response after two consecutive AD trials (7, 8).
Several approaches exist to handle insufficient treatment
response, from combining a non-pharmacological method
[e.g., psychotherapy, electroconvulsive therapy (ECT),
physical exercise] with pharmacotherapy (9–11) to various
pharmacological strategies, including increasing the dose of
the originally administered AD (“dose maximizing”) (10),
adding a second non-AD-type drug (e.g., lithium) to the
already administered AD (“augmentation”), combining the
already administered AD with another AD (“combination”),
and changing the already administered AD to a novel one
(“switching”) (10). However, the efficacy of the above strategies,
and specifically of switching, is underinvestigated in real-life
setting using prospective, open-label, observational studies
in large patient samples in general and especially in the case
of duloxetine.

Frontiers in Psychiatry | www.frontiersin.org

MATERIALS AND METHODS
Participants and Study Design
Of the initially recruited 906 patients at 65 sites for the
investigation of switching to duloxetine involving several
neuropsychiatric diagnoses, 578 eligible participants with MDD
and GAD were enrolled in a multicenter, 8-week, single-arm,
open-label, flexible-dose trial with duloxetine, conducted at
psychiatric clinical practices in Hungary. Sites included only
outpatient providers, such as outpatient psychiatric practices
or outpatient units of psychiatric departments of hospitals.
Only specialist psychiatric settings participated as centers; no
general practice settings were involved. Number of patients
per site ranged between 1 and 30; average number of patients
per site was 9.1. Of the originally involved 65 centers,
patients from 58 sites were included in the present analysis;
patients for the remaining six sites were excluded either for
having only diagnoses other than MDD or GAD, multiple
diagnoses, multiple previous medications, terminated the study
before the final visit or were lost to follow-up. Subjects
were recruited through clinician referrals. Inclusion criteria
included age ≥18 years, current diagnoses of MDD or GAD,
determined on the basis of a psychiatrist-conducted clinical
interview to verify the presence of the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) criteria,
and written informed consent. Psychiatric exclusion criteria
included diagnoses of schizophrenia or other psychotic disorders,
dementia or other cognitive impairment, and drug or alcohol
abuse or dependence within the previous 6 months based
on medical records, unstable general medical conditions, and
lack of capacity to consent to study participation based on
evaluation at inclusion. Patients where duloxetine administration
was contraindicated for psychiatric and somatic reasons as
stated in the Summary of product characteristics (SPC),
including those concomitantly taking non-selective irreversible
monoamine oxidase (MAO) inhibitors or cytochrome P450
(CYP)1A2 inhibitors fluvoxamine, ciprofloxacin, or enoxacin,
presenting with comorbid hepatic impairment or severe liver
disease, severe kidney impairment (creatinine clearance <30
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FIGURE 1 | Flowchart of the progression of participants through the study.

The initial dose of duloxetine was 30, 60, 90, or 120 mg/day,
and the dose was increased according to the clinical response and
patient tolerance (the dose was not fixed), and the maximum dose
was 120 mg/day.

ml/min), or comorbid unstable hypertonia possibly triggering
hypertensive crisis, were also excluded from the study. For the
present analysis, we also excluded those patients who had more
than one psychiatric diagnosis and who were comedicated with
any other psychiatric medication except for benzodiazepines
following initiation of duloxetine treatment. Figure 1 contains an
attrition flow diagram that visualizes the inclusion and exclusion
process. Participants had the right to withdraw at any point
during treatment. The study protocol was reviewed by the
National Scientific and Ethical Committee of Hungary (Reference
No. 60678/2017/EKU). All patients signed an informed consent
form before collection of any data. Study visits were at baseline
(visit 1) and at 4 and 8 weeks (visits 2 and 3, respectively) at which
time the treating psychiatrist administered clinical rating scales.
Safety measures recorded at every visit included spontaneously
reported treatment-emergent adverse events.
Frontiers in Psychiatry | www.frontiersin.org

Measures
Study assessments included a standardized evaluation of
demographic (age, gender) and clinical characteristics as well as
Clinical Global Impression-Severity (CGI-S) at baseline and CGIS and Clinical Global Impression-Improvement (CGI-I) scales
(12), Visual Analog Scale (VAS) for pain (13), satisfaction with
current treatment, and the three-level version of the EuroQol
five-dimensional questionnaire (EQ-5D-3L) at the two follow-up
visits 4 and 8 weeks after initiation of treatment. All assessments
were completed by board-certified psychiatrists.
3
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CGI-S is a 7-point scale where the clinician rates the severity
of the patient’s illness at the time of assessment. Considering total
clinical impression, a patient is assessed on the severity of mental
illness at the time of rating and rated as follows: 1, normal, not
at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill;
5, markedly ill; 6, severely ill; or 7, extremely ill. Besides severity
values, CGI-S was also used to estimate remission, where patients
rated 1 or 2 were considered to be in remission, while patients
rated 3–7 were considered to be non-remitters.
CGI-I is a 7-point scale where the clinician assesses
improvement or worsening of illness severity compared to
baseline as follows: 1, very much improved; 2, much improved; 3,
minimally improved; 4, no change; 5, minimally worse; 6, much
worse; 7, very much worse.
Subjective experience and severity of pain in the present study
was evaluated by a VAS used for digitizing values that cannot be
numerically measured, which started with 0 for “no pain” and
ended with 10 for “very severe pain” and leaving 1 cm between
values giving a numeric value to every centimeter.
Satisfaction with current treatment was rated on an 11-point
Likert scale ranging from 0 = “not at all satisfied” to 10 =
“very satisfied.”
Health status was measured using EQ-5D-3L, which asks
respondents to describe their health using five domains
(mobility, self-care, usual activities, pain/discomfort, and
depression/anxiety). In each domain, respondents indicate
whether they have 1-no problems, 2-some problems, or 3extreme problems on the day of EQ-5D-3L completion, which
were used in calculations involving the individual domains as
numerical values. The health status estimates for the total score
were derived from the UK algorithm in this study to produce
values between 0 and 1, where 1 represents “full health” and 0
represents death (14).

TABLE 1 | Characteristics of patients who completed 8 weeks of treatment.
Characteristics

Number of patients

GAD

n

%

n

%

460

-

105

-

Sex
Male

132

29

44

42

Female

328

71

61

58

Age groups
18–35

37

8

20

19

36–60

270

59

61

58

61–90

153

33

24

23

MDD, major depressive disorder; GAD, generalized anxiety disorder.

throughout the study. In the MDD group, nine participants, and
in the GAD group, four participants were lost to follow-up due
to non-adherence to treatment, low tolerance, or unsatisfactory
treatment efficacy. Finally, 565 participants with MDD or
GAD aged 20–91 years were included in the final analysis.
The sociodemographic data of the samples are summarized
in Table 1.

Medication Used Prior to Switching to
Duloxetine Treatment
In the MDD group, prior to initiating duloxetine at visit 1,
1.2% of the patients were treated with a tricyclic antidepressant
(TCA), 51.7% with a selective serotonin reuptake inhibitor
(SSRI), 12.9% with an SNRI other than duloxetine, 2.4% with
a melatonin MT1/MT2 agonist, 6.1% with an α2 antagonist
(mirtazapine), 3.4% with a selective serotonin reuptake enhancer
(SSRE), and 0.2% with a norepinephrine–dopamine reuptake
inhibitor (NDRI), or reversible inhibitor of monoamine oxidase
(RIMA). The rest of the patients received other medications
(including mood stabilizers, antipsychotics, or anxiolytics). In the
GAD group, 1.0% were taking a TCA, 42.7% an SSRI, 9.4% an
SNRI other than duloxetine, 7.1% mirtazapine, 1% an SSRE, and
the rest an anxiolytic, mood stabilizer, or an antipsychotic before
initiation of duloxetine treatment.

Statistical Methods
Demographic data were examined using independent-samples
t-tests and Fisher’s exact tests for dichotomous variables.
Independent-samples t-tests and repeated-measures ANOVAs
were employed to compare changes in psychometric ratings.
Differences between outcome variables at different time points
were also analyzed by a linear mixed model. The time factor
for the model was set at baseline and weeks 4 and 8. Post-hoc
pairwise comparisons were carried out using paired t-test. Linear
regression analyses were carried out to determine the effects
of dosing. Chi-square tests were used to compare the number
of patients in remission in the two clinical groups at the three
visits. Statistical significance was accepted for p-values <0.05.
Only data from patients completing the study were analyzed. The
statistical analysis was performed using SPSS version 22.0 (IBM
SPSS Statistics, Chicago, IL, USA).

Duloxetine Dosing and Dose Adjustment
During the Study Visits in the Analyzed
Dataset of Patients Completing the Study
The initial dose of duloxetine was 30, 60, 90, or 120 mg/day, and
the dose was increased according to clinical response and patient
tolerance (the dose was not fixed), and the maximum dose was
120 mg/day.
At the first visit, in the MDD group, the starting dose
was 30 mg in 30.65%, 60 mg in 45.44%, 90 mg in 23.26%, and
120 mg in 0.65% of the patients, while in the GAD group, initial
duloxetine dose was 30 mg in 42.86%, 60 mg in 46.67%, 90 mg in
10.48%, and 120 mg in 0.95% of the patients. The most common
starting dose was 60 mg in both groups (Table 2).
During the second visit at 4 weeks, in the MDD group,
59.56% of patients continued their dose, the dose was increased in

RESULTS
Participant Flow
A total of 578 participants were included in the study and
assigned to two groups: 469 participants to the MDD and 109
to the GAD. Figure 1 shows the progression of participants

Frontiers in Psychiatry | www.frontiersin.org

MDD

4

June 2021 | Volume 12 | Article 689143

Szekeres et al.

Observation Study of Duloxetine

TABLE 2 | Doses of duloxetine and dose adjustments during the 8-week study period in MDD and GAD patients.
Visit 1

Visit 2

Visit 3

MDD

GAD

MDD

GAD

MDD

GAD

N

460

105

460

105

460

105

Minimum dose, mg

30

30

30

30

30

30

Maximum dose, mg

120

120

120

120

120

120

58.17

50.86

71.15

66.57

74.74

70.57

60

60

60

60

90

60

Dose increased from previous visit N (%)

185 (40.22%)

53 (50.48%)

58 (12.61%)

15 (14.29%)

Dose continued from previous visit N (%)

274 (59.56%)

52 (49.52%)

398 (86.52%)

89 (84.76%)

Dose decreased from previous visit N (%)

1 (0.22%)

0 (0%)

4 (0.87%)

1 (0.95%)

Mean dose increase from previous visit mg

32.43

31.13

30.52

30

Mean dose decrease from previous visit mg

30

0

30

30
15 (14.29%)

Mean dose, mg
Median dose, mg

30 mg, N (%)

141 (30.65%)

45 (42.86%)

44 (9.57%)

15 (14.29%)

42 (9.13%)

60 mg, N (%)

209 (45.44%)

48 (46.67%)

212 (46.09%)

54 (51.43%)

168 (36.52%)

41 (39.05%)

90 mg, N (%)

107 (23.26%)

11 (10.48%)

193 (41.96%)

34 (32.38%)

232 (50.43%)

46 (43-81%)

120 mg, N (%)

3 (0.65%)

1 (0.95’%)

11 (2.39%)

2 (1.90%)

18 (3.91%)

3 (2.86%)

MDD, major depressive disorder; GAD, generalized anxiety disorder; N, number of patients; %, percentage of patients.

p = 0.032 for GAD and MDD groups, respectively; see Table 3).
Age and sex were not significant covariates, except of CGI-S
in GAD.

40.22%, and one patient (0.22%) had dose reduction. In the GAD
group, 49.52% of patients continued their initial dose, 50.48% had
dose increase, and no patient had dose decrease. The mean dose
at the second visit was 71.15 mg in the MDD group and 66.57 mg
in the GAD group (Table 2).
During the third visit at 8 weeks, in the MDD group, 86.52%
continued their dose from the previous visit, 12.1% had dose
increase, and 0.87% of patients had dose decrease. In the GAD
group, 84.76% of patients continued their previous dose, 14.29%
had dose increase, and 0.95% had dose decrease. The mean doses
at the third visit were 74.74 mg in the MDD group and 70.57 mg
in the GAD group. The median dose was 60 mg in all visits in
both patient groups except at the third visit wherein the median
dose was 90 mg in the MDD group (Table 2).

Health Status and Subjective Experience of
Pain
Overall health status, as measured by EQ-5D-3L, as well as all
five of its status indicators (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression) also significantly showed
improvement with time during the 8 weeks of duloxetine therapy
in both groups (p < 0.001 in both groups; see Table 3). A
significant improvement over time during the whole study period
was also observable for subjective experience of pain in both
groups (p < 0.001; see Table 2). Bonferroni post-hoc tests revealed
that all differences were statistically significant both from baseline
to visit 2 at 4 weeks and from visit 2 at 4 weeks to visit 3 at 8 weeks,
except for no significant differences between the second and third
visits in the GAD group for EQ-5D-3L for mobility (p = 0.1863)
and self-care (p = 0.4380).
Linear regression analysis showed a significant effect of dose
only in the MDD group on EQ-5D-3l total scores (p < 0.0001).
Age and sex were not significant covariates.

Efficacy Evaluation
Severity of illness in both clinical groups significantly decreased
over the 8-week study period according to CGI-S score (p < 0.001
in both groups; see Table 3). Parallel with this, a significant
improvement in illness severity over the study period was
also observable according to the CGI-I scale in both groups
(p < 0.001 in both groups; see Table 3). Bonferroni post-hoc tests
revealed that all differences were statistically significant, both
from baseline to visit 2 at 4 weeks and from visit 2 at 4 weeks
to visit 3 at 8 weeks.
When considering those with CGI-S score <3 to be in
remission, in case of MDD, 0.43, 12.83, and 41.3% of patients
were in remission at baseline (patients in remission at baseline
were switched to duloxetine due to tolerability problems), 4 and 8
weeks, respectively [chi-square (2,460) = 268.3042, p < 0.00001].
In case of GAD patients, 0.95, 19.05, and 54.28% of patients
achieved remission at baseline, 4 and 8 weeks of treatment,
respectively [chi-square (2,105) = 82.9163, p < 0.00001].
Linear regression analysis showed a significant effect of dose
on changes in CGI-S in GAD and MDD patients (p = 0.024 and

Frontiers in Psychiatry | www.frontiersin.org

Satisfaction With Treatment
During the whole 8-week study period, satisfaction with
treatment significantly increased in both groups over the 8-week
study period (p < 0.001 in both groups; see Table 3) and from
visit 1 to visit 2 and from visit 2 to visit 3 according to Bonferroni
post-hoc tests (p < 0.001 for both groups and both cases).
Linear regression analysis showed a significant effect of
initial dose on satisfaction with current treatment only in the
MDD group (p = 0.007; see Table 3). Age and sex were not
significant covariates.
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TABLE 3 | Outcome measures for patients treated with duloxetine and effects of dosing.
Baseline

4 weeks
Mean

SD

8 weeks
Mean

Over time variation p-value

Effects of dosing (Baseline vs. 8 weeks)

Mean

SD

SD

4.38

0.92

3.35

1.08

2.50

1.15

<0.001

β = −0.21 (p = 0.024)

-

-

2.55

0.83

1.83

0.84

<0.001

-

Subjective experience of pain (VAS)

3.17

3.02

2.07

2.46

1.57

2.36

<0.001

n.s.

Satisfaction with current treatment

4.07

2.08

6.93

2.33

8.36

2.24

<0.001

n.s.

EQ-5D-3L

0.55

0.20

0.72

0.18

0.84

0.16

<0.001

n.s.

GAD (N = 105)
Clinical global impression
Severity (CGI-S)
Improvement (CGI-I)

Mobility

1,27

0,44

1,14

0,35

1,09

0,28

<0.001

-

Self-care

1.22

0.42

1.10

0.30

1.07

0.25

<0.001

-

Usual activities

1.66

0.60

1.35

0.52

1.15

0.36

<0.001

-

Pain/discomfort

1.86

0.60

1.57

0.59

1.36

0.50

<0.001

-

Anxiety/depression

2.40

0.49

2.09

0.28

2.02

0.14

<0.001

-

4.71

0.83

3.63

1.01

2.72

1.12

<0.001

β = −0.10 (p = 0.032)

-

-

2.56

0.74

1.85

0.76

<0.001

-

Subjective experience of pain (VAS)

4.92

3.08

3.04

2.46

1.86

1.91

<0.001

n.s.

Satisfaction with current treatment

4.11

2.10

7.16

2.12

8.27

2.18

<0.001

β = 0.13 (p = 0.007)

EQ-5D-3L

0.45

0.21

0.68

0.19

0.81

0.17

<0.001

β = 0.17 (p = 0.000)

MDD (N = 460)
Clinical global impression
Severity (CGI-S)
Improvement (CGI-I)

Mobility

1.45

0.51

1.30

0.46

1.22

0.42

<0.001

-

Self-care

1.32

0.49

1.17

0.39

1.04

0.29

<0.001

-

Usual activities

1.90

0.64

1.44

0.56

1.22

0.43

<0.001

-

Pain/discomfort

2.21

0.62

1.75

0.53

1.48

0.43

<0.001

-

Anxiety/depression

2.48

0.50

2.10

0.30

2-01

0.10

<0.001

-

MDD, major depressive disorder; GAD, generalized anxiety disorder; CGI-S, Clinical Global Impression-Severity; CGI-I, Clinical Global Impression-Improvement; VAS, Visual Analog
Scale; EQ-5D-3L, three-level version of the EuroQol five-dimensional questionnaire.

Adverse Effects

patients reported adverse effects (0.86%), which led to treatment
termination in two cases (0.43%).

In the case of the GAD group, of the initially included 109
patients, two (1.83%) patients reported adverse effects at the
second visit at 4 weeks. In one case, there was verified association,
and in the other, possible association with duloxetine treatment.
In the case of one patient, the side effects were mild and did not
require intervention, while in the other case, the reported side
effect was severe and led to termination of duloxetine treatment
at 4 weeks (0.92%). At the third visit, after 8 weeks of treatment,
one (0.93%) patient reported moderately severe side effects likely
related to duloxetine, leading to termination of treatment in the
GAD group. Altogether, during the 8 weeks of the study, of the
109 included patients, three reported adverse effects of different
severities (2.75%) and two had to terminate treatment (1.83%).
In the case of MDD, of the initially involved 464 patients, at
the second visit after 4 weeks, three patients (0.65%) reported
adverse effects, with possible, likely, and verified association with
duloxetine. Side effects were mild in two cases not requiring
intervention and moderately severe in one case where duloxetine
treatment was terminated (0.22%). At the third visit, one patient
reported a mild adverse effect likely related to duloxetine, which
led to treatment termination at 8 weeks (0.22%). Altogether,
during the 8-week study period in the MDD group, four

Frontiers in Psychiatry | www.frontiersin.org

DISCUSSION
In our present 8-week, multicenter, flexible-dosing, single-arm,
open-label, observational real-life study in MDD and GAD
patients switched to duloxetine after inadequate response or
tolerability to other ADs, we observed a significant positive
effect on all outcome measures, including a significant decrease
in illness severity as well as significant overall symptomatic
improvement. By the end of the 8-week treatment, 41.3% of
MDD and 54.28% of GAD patients previously non-responding
to AD treatment and switched to duloxetine reached remission,
as indicated by a score <2 on the CGI-S. Furthermore, a
significant improvement in all self-rated health status dimensions
including mobility, self-care, usual activities, pain/discomfort,
or anxiety/depression and significant improvement of subjective
experience of pain were observable in the case of both diagnoses.
A steady and significant improvement of satisfaction with
treatment was also observable during the study. Finally, a
significant effect of initial treatment dose was also observed for
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change in severity of overall symptoms in both groups, with a
larger decrease for a higher initial dose, and for satisfaction with
treatment and health status in GAD patients, where a larger
initial dose was associated with higher satisfaction and more
improved health status. Overall, our results support beneficial
effects of switching to duloxetine in patients not responding to
other conventional and newer-generation ADs in MDD or GAD
or who had intolerable side effects from their previous AD.
Duloxetine has been approved for the treatment of various
psychiatric diagnoses including MDD and GAD. Especially in the
case of MDD, there is a significant proportion of patients not
adequately responding to first treatment trials, and ∼35% can
be considered treatment resistant (15) as not responding to the
first two trials of adequate ADs. In the case of GAD, while SSRIs
and SNRIs are recommended as first-line treatment, there is no
relevant clinical evidence choosing between the medications and
up to half of patients do not respond adequately to treatment (16).
Thus, switching treatment due to lack of efficacy or suboptimal
tolerability is a frequent clinical practice. Finding the right
treatment in several cases requires several attempts and trials,
which significantly extends the suffering of patients and leads
to increased economic costs in terms of both treatment and loss
of functionality.

placebo was associated with the highest change of symptoms
from baseline (with a mean difference of −3.0, 95% CI: −4 to
−2.2) and had the second highest response rate [odds ratio (OR):
2.1, 95% CI: 1.6–2.2] after venlafaxine (21). For MDD patients in
a similar network meta-analysis with 21 ADs for acute treatment
(22), duloxetine was the third most efficacious drug in terms of
response rates after amitriptyline and mirtazapine with an OR
of 1.85 (95% CI: 1.66–2.07). While our CGI-S-based remission
rate for depression is in the lower range of those observed
for duloxetine in previous studies, it must be noted that our
patients were non-responders to at least one previous treatment,
so this population may contain a higher than usual proportion
of treatment-resistant depressed patients. On the other hand, in
the case of GAD patients, remission rates (based on CGI-S) in
the present study were significantly higher than figures reported
previously in non-switched patients, possibly suggesting that the
second choice of treatment in those patients who do not respond
to initial therapy leads to remission in a larger portion of patients
in the case of GAD.

Efficacy of Switching to Duloxetine
Treatment Over 8 Weeks in Major
Depressive Disorder and Generalized
Anxiety Disorder Patients

Notably, beyond significantly decreasing symptom severity,
functionality-related health status measures such as self-care,
pursuing of usual activities, and mobility also showed significant
improvement in both groups already at the fourth week of
treatment with an overall significant increase in EQ-5D-3L in
both groups and with further increase from the fourth week to the
eighth week in the total score as well as all sub-measures in the
MDD group. However, in GAD patients, no further significant
improvement in mobility and self-care was observable beyond
week 4 of duloxetine treatment. Furthermore, a significant effect
of dose was observed on improvement on EQ-5D-3L total
score only in the MDD group, with bigger improvement for
higher doses.

Effects of Switching to Duloxetine on
Functionality-Related Health Status in
Major Depressive Disorder and
Generalized Anxiety Disorder Patients

In our observational study, the significant overall improvement,
symptomatic decrease, and increase in proportion of remitted
patients signify that duloxetine may be a beneficial choice for
MDD and GAD patients requiring a switch due to non-response
to other treatments. In our 8-week trial, not only did we observe
a significant improvement along all measures by completion of
the trial but also the improvement was observable in severity
measures already at the fourth week of treatment in both MDD
and GAD patients. Further significant improvement continued
all through the second follow-up visit, 8 weeks after initiation
of switch, where 41.3% of MDD and 54.28% of GAD patients
reached remission corresponding to a CGI-S score <2, which
is in line with previous results and models. Following acute
treatment with ADs in general, ∼37% of MDD patients reach
remission by week 9 [based on a Patient Health Questionnaire
(PHQ)-9 score of 4 or less] (17), while in the case of acute
duloxetine treatment, remission rates are reported between 44
and 55% in placebo-controlled studies using various instruments
(18). In the case of GAD, approximately one-third to one-half
of patients achieve remission with 8–9 weeks of acute treatment
with ADs in general (19), while remission rates between 31
and 38% have been reported in acute 60–120-mg duloxetine
treatment of GAD patients in double-blind, placebo-controlled
studies (20). It must be noted that in our study, we investigated
patients switched from other ADs mostly due to inadequate
response. In a network meta-analysis of eight ADs for the
treatment of GAD involving placebo-controlled and head-tohead comparison studies (21), duloxetine in comparison to
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Effects of Switching to Duloxetine
Treatment on Subjective Experience of
Pain in Generalized Anxiety Disorder and
Major Depressive Disorder Patients
As pain is a frequent but often overlooked symptom of depression
and anxiety disorders (23, 24) that often persists as a residual
symptom in spite of treatment significantly impairing quality of
life (25, 26), we also looked at the effect of switching to duloxetine
treatment on subjective evaluation of pain. In both MDD
and GAD patients, subjective ratings of pain were significantly
reduced during the 8-week study period according to both the
VAS evaluation and the pain/discomfort subscale of EQ-5D-3L
in both groups. Along both measures of pain, significant effect in
both groups appeared already in the fourth week of treatment and
further significant improvement continued through the eighth
week. Notably, there was no significant dose effect on pain
measurement by VAS in either the MDD or the GAD groups.
In previous double-blind, placebo-controlled acute treatment
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studies of duloxetine in MDD, a significant improvement in
painful physical symptoms was also observed (27) and often
as early as the second week of the study (18). Furthermore, in
previous double-blind, placebo-controlled studies in the acute
treatment of GAD, duloxetine was also significantly effective in
improving subjective feelings of pain (20). Thus, our open-label
naturalistic study in a clinical setting confirms previous findings
on the beneficial effects of duloxetine on pain associated with
affective disorders.

those seen in placebo–controlled, double-blind trials. Also, in the
lack of comparators, outcome measures can only be compared
to baseline values. At the same time, an open–label, singlearm study more closely resembles standard clinical practice
than double-blind, placebo-controlled designs, providing the
possibility for more realistic observations especially given the
large sample size employed in our present analysis (29). A further
shortcoming of our study is that diagnoses were ascertained
by clinical interviews administered by a psychiatrist but not
structured instruments, and scales for the assessment of specific
depressive and anxious symptoms were not used. Accordingly,
we were unable to ascertain the effect of duloxetine treatment
on the given symptoms of MDD and GAD. The final limitation
is the relatively short 8-week assessment period; a longer study
period would have allowed for the more precise observation of
later emerging adverse effects as well as relapse rates.

Satisfaction With Treatment During the
8-Week Duloxetine Treatment Period
As satisfaction with treatment is a central factor determining
treatment adherence, compliance, and persistence (28), we
specifically looked at self-reports of patients on satisfaction with
their current duloxetine treatment. Satisfaction significantly
improved with time in both MDD and GAD groups;
furthermore, a significant effect of dose was observable
only for the MDD group but not the GAD group with higher
satisfaction with higher doses. Besides the significant increase,
the fact that at the third visit (8 weeks), in GAD patients, the
mean score of satisfaction was 8.36 and, in MDD patients, 8.27
from a maximum of 10 indicates good acceptability of duloxetine
in our patient populations.

CONCLUSION
Overall, results of our naturalistic, observational study in a
large population of MDD and GAD patients indicate beneficial
effects of duloxetine on illness severity, functional outcomes, and
subjective experience of pain. We also found good satisfaction
with treatment and good tolerability in both GAD and MDD
groups and even in patients who had to switch treatment due to
lack of response to other ADs.

Adverse Reactions During 8 Weeks of
Switching to Duloxetine Treatment
The very low numbers of both GAD and MDD patients who
reported adverse effects (2.75 and 0.86% in the GAD and
MDD groups, respectively) and had to terminate treatment
due to these adverse reactions (1.83 and 0.43% in the GAD
and MDD groups, respectively) are much lower than the 12–
14% adverse event-related discontinuation rates reported in
previous double-blind, placebo-controlled studies for MDD (18,
29–31) and the 5% of adverse events in double-blind, placebocontrolled acute duloxetine treatment studies of GAD (20). In
GAD patients, in a network meta-analysis of eight ADs for
acute treatment, although duloxetine was found to be effective,
its acceptability and tolerability were found to be lower than
placebo and other drugs such as venlafaxine and escitalopram
(21). In a similar network meta-analysis of 21 ADs in the acute
treatment of MDD, duloxetine was among the medications with
the highest dropout rates as one of the least tolerable drugs,
with worse tolerability compared to several other drugs including
escitalopram, fluoxetine, paroxetine, sertraline, and vortioxetine
(22). Thus, our real-life results in a naturalistic clinical setting
suggest that duloxetine may be significantly better tolerated in
both MDD and GAD patients than suggested by double-blind,
placebo-controlled trials.
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